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C-Reactive Protein
A New Predictor of Adverse
Outcome in Pulmonary Arterial Hypertension
Rozenn Quarck, PHD,* Tim Nawrot, PHD,†‡ Bart Meyns, MD, PHD,§ Marion Delcroix, MD, PHD*
Leuven and Diepenbeek, Belgium
Objectives Our aim was to investigate in a prospective study a potential role of C-reactive protein (CRP) in predicting the
outcome in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension
(CTEPH).
Background CRP is a well-known marker of inflammation and tissue damage, widely recognized as a risk predictor of cardio-
vascular and coronary heart diseases.
Methods Plasma levels of CRP have been measured in consecutive patients diagnosed with PAH and CTEPH, at the time
of right heart catheterization.
Results Circulating CRP levels were increased in CTEPH and PAH patients compared with those in control subjects (4.9
mg·l1, 95% confidence interval [CI]: 3.9 to 6.2 mg·l1; 4.4 mg·l1, 95% CI: 3.5 to 5.4 mg·l1; and 2.3 mg·l1,
95% CI: 1.9 to 2.7 mg·l1, respectively; p  0.0001). In PAH patients, CRP levels correlated with New York
Heart Association functional class (r  0.23), right atrial pressure (r  0.25), and 6-min walking distance (r 
0.19) and were significantly higher in nonsurvivors than in survivors (p  0.003). All PAH, idiopathic PAH, and
patients naive for disease-specific medication with CRP levels 5.0 mg·l1 had a significantly lower survival rate
(p  0.02, p  0.009, and p  0.05, respectively). In CTEPH patients, circulating CRP levels significantly de-
creased 12 months after pulmonary endarterectomy (n  23, 4.0 mg·l1, 95% CI: 2.8 to 5.8 mg·l1, to 1.6
mg·l1, 95% CI: 2.2 to 3.0 mg·l1; p  0.004). PAH patients normalizing their CRP levels under treatment (n 
29), assigned as responders, had a significantly higher survival rate (p  0.05). The proportion of patients
treated with a parenteral prostacyclin-analogue was significantly higher among the responders than the nonre-
sponders (55% vs. 17%, p  0.002).
Conclusions This is the first evidence of a role of an inflammatory marker, such as CRP, in predicting outcome and response
to therapy in PAH. (J Am Coll Cardiol 2009;53:1211–8) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.038v
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pulmonary hypertension is a rare and severe disorder,
haracterized by an elevated pulmonary arterial pressure
PAP). On the basis of common clinical features, 5 catego-
ies of pulmonary hypertension have been identified (1).
mong them, pulmonary arterial hypertension (PAH) is
haracterized by an intrinsic distal vessel arteriopathy and
hronic thromboembolic pulmonary hypertension (CTEPH)
y proximal vessel occlusions occasionally followed by distal
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Occupational, Environmental and Insurance Medicine, Public Health Department,
atholieke Universiteit Leuven, Belgium; ‡School of Life Sciences, Hasselt Univer-
ity, Diepenbeek, Belgium; and the §Cardiac Surgery Department, Universitaire
iekenhuizen, Leuven, Belgium. Dr. Delcroix received research grants and speaker
ees from Actelion, Encysive, Pfizer, and LungRx. Dr. Delcroix is holder of the
ctelion chair for pulmonary hypertension at the Katholieke Universiteit Leuven. Dr.
awrot is the recipient of a fellowship from the Fonds voor Wetenschappelijk
nderzoek-Vlaanderen.(
Manuscript received September 5, 2008; revised manuscript received December 2,
008, accepted December 8, 2008.essel remodeling. The pathophysiological processes com-
only involved in PAH include vasoconstriction, vascular
emodeling, and thrombosis (2). Although inflammatory cell
nfiltrates had been observed around the distal pulmonary
rteries (3), the potential role of inflammation in the
athogenesis of PAH has only recently been investigated.
ncreased plasma levels of interleukin-1, interleukin-6, and
X3C chemokine fractalkine (4,5) and increased expression
f CCL3 chemokine macrophage inflammatory protein-1
lpha in lung biopsies (6) have been reported. In CTEPH,
ysregulated thrombosis and/or thrombolysis, as causes of
ntraluminal thrombus organization and fibrous vessel oblit-
ration, have been inconsistently evidenced (7). Recent
orks also suggest the importance of systemic inflammation
n the genesis of the disease. The CCL2 chemokine
onocyte chemoattractant protein-1 is up-regulated in
lasma and in large pulmonary arteries of CTEPH patients
8). An increased prevalence of inflammatory disease in
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acute pulmonary embolism has
been reported (9).
C-reactive protein (CRP) is a
marker of inflammation and tis-
sue damage. It has been identi-
fied as a predictor of risk for
cardiovascular events (10). Be-
sides its commonly accepted role
of bystander and marker of clin-
ical risk in various inflammatory
diseases, CRP may also be an
active player in the physiopathol-
ogy of the vascular wall, as dem-
onstrated in atherosclerosis (11).
The role of CRP in pulmonary
hypertension is completely un-
known. The aim of the present
study was to investigate a poten-
tial role of CRP as a predictor of
pulmonary hypertension severity
and outcome.
Methods
Study population. This prospec-
tive study included all consecutive
patients diagnosed with PAH and
CTEPH, as defined by the
Venice classification (1), who un-
derwent right heart catheteriza-
tion at the University Hospital of
euven between April 1, 2004, and April 30, 2008. Healthy
ubjects were recruited out of screening programs from the
epartments of urology and gynecology. The study protocol
as been approved by the Institutional Ethics Committee of
he University Hospitals Leuven, and participants gave
nformed consent.
linical parameters. Medical records of the patients were
eviewed, and the following data were extracted: sex, age,
eight and size, modified New York Heart Association
NYHA) functional class (1), 6-min walking distance
6MWD), current disease-specific drug use (prostacyclin
nalogues, endothelin receptor antagonists, and phosphodi-
sterase inhibitors) at the time of catheterization, date of
ymptom onset, and date of diagnosis. At study entry,
atients and healthy control subjects completed a question-
aire that provided information about smoking habits, and
istory of diabetes mellitus and hypertension. The right
eart catheterization included measurements of mean right
trial pressure (RAP), PAP, pulmonary vascular resistance
PVR), and cardiac index. PAH and CTEPH patients were
tratified into subgroups of low versus high disease severity
ccording to NYHA functional class (I to II or III to IV).
or survival and event-free survival, the observation period
Abbreviations
and Acronyms
CI  confidence interval
CRP  C-reactive protein
CTEPH  chronic
thromboembolic pulmonary
hypertension
IPAH  idiopathic
pulmonary arterial
hypertension
NT-proBNP  N-terminal
fragment of brain
natriuretic peptide
NYHA  New York Heart
Association
PAH  pulmonary arterial
hypertension
PAP  mean pulmonary
arterial pressure
PEA  pulmonary
endarterectomy
PVR  pulmonary vascular
resistance
RAP  mean right atrial
pressure
ROC  receiver-operator
characteristic
ULN  upper limit of
normal
6MWD  6-min walking
distanceas from study entry until death or June 25, 2008. Death, iung transplantation, and start of parenteral prostacyclin
nalogues were assigned as clinical worsening events.
lood samples. Blood samples were collected on
thylenediaminetetra-acetic acid at the time of right heart
atheterization, and plasma was prepared. CRP levels
Tina-quant C-Reactive Protein, Roche Diagnostics, Vil-
oorde, Belgium) were determined in the University Hos-
ital routine laboratory. The upper limit of normal (ULN)
as 5 mg·l1.
tatistical analysis. Database management and statistical
nalyses were performed using SAS software version 9.1
SAS Inc., Cary, North Carolina) and GraphPad Prism
ersion 4.01 (GraphPad Software Inc., La Jolla, California).
ontinuous and normally distributed values were expressed
s mean  SD. Values not normally distributed were
og-transformed to normalize their distribution and ex-
ressed as a geometric mean with a 95% confidence interval
CI). Differences between the 3 groups were analyzed using
nalysis of variance followed by post-hoc tests (Bonferroni)
or continuous variables and a chi-square test for categorical
ariables. Differences between 2 groups were compared
sing a Student t test. Differences within groups before and
fter treatment were analyzed using a paired t test. Associ-
tions between variables were investigated using Pearson
orrelation. Survival curves for patients were contrasted with
aseline levels of CRP above and below the ULN by
aplan-Meier survival function estimate and log-rank test.
he sensitivity and specificity of CRP to predict survival
as assessed by a receiver-operator characteristic (ROC)
nalysis. Cox regression was applied to model the relation
etween failure time (time to death for PAH, and time to
eath or persistent pulmonary hypertension for CTEPH,
efined by a PAP 35 mm Hg at 3 days post-surgery) and
he plasma CRP concentration at baseline, adjusting for
ther explanatory variables including sex, age, body mass
ndex, smoking status (current and past), PAP, RAP, PVR,
ardiac index, NYHA functional class, etiology, and
MWD. We identified covariates by a stepwise regression
rocedure with the p values for variables to stay in the model
et at 0.10. Covariates considered for entry in the model
ere age, sex, body mass index, smoking status, PAP, RAP,
VR, cardiac index, NYHA functional class, 6MWD,
tiology, and logCRP. All p values were for 2-sided tests. A
alue of p  0.05 was considered statistically significant.
esults
haracteristics of the study population. One hundred
nd four patients with PAH, 79 patients with CTEPH, and
control group of 95 healthy subjects were included in the
tudy. Patient demographics and clinical characteristics at
tudy entry are reported in Table 1. Among the PAH
atients, 50 (49%) had idiopathic pulmonary arterial hyper-
ension (IPAH) and 54 (51%) had PAH associated to other
iseases including connective tissue disease (24%), congen-
tal heart disease (7%), portal hypertension (10%), myelo-
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April 7, 2009:1211–8 CRP and Pulmonary Arterial Hypertensionroliferative disorders (5%), pulmonary veno-occlusive dis-
ase (3%), drug abuse (1%), and human immunodeficiency
irus (1%). Sixty-seven (68%) PAH patients were naive for
isease-specific medication. Among the CTEPH patients,
8 (75%) had a history of acute venous thromboembolism
nd 53 (66%) had at least 1 thrombophilic disorder. During
he observation period (mean 786 days, range 4 to 1,554
ays), 27 PAH and 8 CTEPH patients died. Forty-four
56%) CTEPH patients underwent a pulmonary endar-
erectomy (PEA). Nine PAH patients underwent a lung
ransplantation, and 11 started intravenous or subcutane-
us prostacyclin analogues.
RP and severity in PAH. Circulating CRP levels were
ignificantly higher in CTEPH and PAH patients (4.9
g·l1, 95% CI: 3.9 to 6.2 mg·l1 and 4.4 mg·l1, 95% CI:
.5 to 5.4 mg·l1) compared with those seen in control
ubjects (2.3 mg·l1, 95% CI: 1.9 to 2.7 mg·l1, analysis of
ariance p  0.0001) (Fig. 1). CRP levels were not
tatistically different between the different subcategories of
AH.
In PAH patients, CRP levels correlated with NYHA
unctional class (r  0.23, p  0.02) and RAP (r  0.25,
 0.01) and inversely correlated with 6MWD (r 
0.19, p  0.04). CRP levels were significantly higher in
YHA functional class III to IV compared with those seen
n NYHA functional class I to II (5.9 mg·l1, 95% CI: 4.4
o 7.9 mg·l1 vs. 3.2 mg·l1, 95% CI: 2.3 to 4.3 mg·l1,
 0.004) and in nonsurvivors compared with those seen in
haracteristics of the Study Population
Table 1 Characteristics of the Study Population
PAH
(n  104)
CTEPH
(n  79)
Control
Subjects
(n  95)
p Value
(ANOVA,
Chi-Square)
Age, yrs 58 15 62 14* 56 16 0.02
BMI, kg/m2 26 6 28 6 26 5 0.10
Sex, female, % 66 62 54 0.18
Ever smoking, % 46 57 51 0.35
Current 33 18 17 0.09
Past 67 82 83 —
Diabetes type II, % 13.9 10.1 6.3 0.18
AHT, % 26.9 38.0 18.9 0.01
PAP, mm Hg 50 13 45 11 ND 0.004
RAP, mm Hg 9 6 7 5 ND 0.11
PVR, dyne·s·cm5 850 397 804 381 ND 0.43
Cardiac index, l·min1·m2 2.42 0.81 2.19 0.53 ND 0.02
6MWD, m 335 162 322 148 ND 0.59
NYHA functional class, n 2.5 0.8 2.8 0.5 ND 0.02
I 10 0 ND —
II 40 22 ND —
III 43 52 ND —
IV 11 5 ND —
p  0.05 versus control.
AHT  arterial systemic hypertension; ANOVA  analysis of variance; BMI  body mass index;
TEPH  chronic thromboembolic pulmonary hypertension; ND  not done; NYHA  New York
eart Association; PAH  pulmonary arterial hypertension; PAP  mean pulmonary arterial
ressure; PVR pulmonary vascular resistance; RAPmean right atrial pressure; 6MWD 6-min
alking distance.urvivors (8.3 mg·l1, 95% CI: 5.0 to 13.6 mg·l1 vs. 3.6g·l1, 95% CI: 2.9 to 4.5 mg·l1, p  0.0008). This last
bservation was also found in IPAH patients (8.0 mg·l1,
5% CI: 3.3 to 19.2 mg·l1 vs. 3.6 mg·l1, 95% CI: 2.7 to 4.8
g·l1, p  0.02) and in treatment-naive PAH patients (8.5
g·l1, 95% CI: 4.3 to 16.7 mg·l1 vs. 3.6 mg·l1, 95% CI:
.7 to 4.9 mg·l1, p 0.03). The nonsurvivors also had a lower
MWD (233  150 m vs. 371  152 m, p  0.0001) and a
igher RAP (12 6 mm Hg vs. 8 5 mm Hg, p 0.0002)
nd NYHA functional class (2.8  0.7 vs. 2.4  0.8, p 
.01). Severity did not affect CRP levels in CTEPH patients.
RP as a predictor of outcome in PAH. Survival Kaplan-
eier analyses showed that all PAH, IPAH, and
reatment-naive PAH patients with CRP levels higher than
LN had a significantly lower survival rate (2-year survival
f 65% vs. 82%, p 0.02 [Fig. 2A]; 61% vs. 96%, p 0.009
Fig. 2B]; and 63% vs. 87%, p  0.05 [Fig. 2C], respec-
ively). In accordance, all PAH, IPAH, and treatment-naive
AH patients with CRP  ULN had a higher NYHA
unctional class (p  0.02, p  0.02, and p  0.003,
espectively) and a lower 6MWD (p  0.0001, p  0.01,
nd p  0.0009, respectively), without any significant
ifferences in the hemodynamic profile.
Similarly, event-free survival Kaplan-Meier analyses
howed that all PAH, IPAH, and treatment-naive PAH
atients with CRP  ULN had a significantly lower
vent-free survival rate (2-year event-free survival of 57% vs.
6%, p 0.01 [Fig. 2D]; 54% vs. 95%, p 0.009 [Fig. 2E];
nd 63% vs. 78%, p  0.04 [Fig. 2F], respectively).
ccordingly, the significantly lower CRP levels observed in
vent-free PAH patients (3.6 mg·l1, 95% CI: 2.8 to 4.6
g·l1 vs. 6.3 mg·l1, 95% CI: 4.3 to 9.4 mg·l1, p 0.01)
nd in event-free treatment-naive PAH patients (3.5
g·l1, 95% CI: 2.5 to 4.9 mg·l1 vs. 6.5 mg·l1, 95% CI:
.9 to 10.7 mg·l1, p  0.04) were accompanied by a
ignificantly lower NYHA functional class (p  0.01 and
Control PAH CTEPH
1
10
100
** **
-1
)
Figure 1 CRP Levels in Patients With Pulmonary Hypertension
C-reactive protein (CRP) levels were measured in plasma of patients with pul-
monary arterial hypertension (PAH) (n  104), chronic thromboembolic pulmo-
nary hypertension (CTEPH) (n  79), and control subjects (n  95). Black
lines represent geometric mean. Analysis of variance, p  0.0001;
**p  0.01 versus control.
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CRP and Pulmonary Arterial Hypertension April 7, 2009:1211–8 0.007, respectively) and RAP (p 0.005 and p 0.01,
espectively) and a higher 6MWD (p  0.0003 and p 
.006, respectively).
All PAH and IPAH patients with a CRP  ULN had a
ignificantly lower time to death (1.7  1.2 years vs. 2.3 
.3 years, p  0.04; 1.8  1.2 years vs. 2.7  1.3 years, p 
.02, respectively), without any significant change in time to
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Figure 2 Survival and Event-Free Survival in PAH Patients Acco
Kaplan-Meier curves comparing survival (A to C) and event-free survival rates (D t
patients (n  104); (B and E) idiopathic pulmonary arterial hypertension (IPAH) pa
Figure 1.linical worsening. 4According to ROC analyses, CRP plasma levels of 4.75,
.9, and 5.0 mg·l1, respectively, were the best cutoff values
or all PAH, IPAH, and treatment-naive PAH patients.
ensitivity was 63% (95% CI: 42% to 81%) and specificity
4% (95% CI: 52% to 74%) for all PAH patients, 70% (95%
I: 35% to 93%) and 69% (95% CI: 51% to 81%) for IPAH
atients, and 62% (95% CI: 35% to 85%) and 63% (95% CI:
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uring the follow-up of PAH patients with CRP 5 or 5 mg·l1. (A and D) All PAH
(n  50); (C and F) treatment-naive PAH patients (n  67). Abbreviations as inF
E
D
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o F) d
tients8% to 76%) for treatment-naive PAH patients.
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April 7, 2009:1211–8 CRP and Pulmonary Arterial HypertensionThe univariate analysis showed that age, etiology,
YHA functional class, 6MWD, RAP, and CRP signif-
cantly predicted mortality of all PAH and treatment-naive
AH patients (Table 2). Only 6MWD and CRP signifi-
antly predicted mortality of IPAH patients (Table 2). Both
efore (Fig. 2) and after adjustment for potential confound-
ng variables, plasma CRP predicted mortality of all PAH,
PAH, and treatment-naive PAH patients (Table 2). Inde-
endent of the other covariates, a doubling of the plasma
RP level was associated with a 41% (95% CI: 9% to 81%,
 0.008) increase in the risk for a fatal event. The
orresponding hazard ratios for IPAH and treatment-naive
AH patients were 100% (95% CI: 6% to 290%, p 0.033)
nd 48% (95% CI: 10% to 99%, p  0.009), respectively
Table 2). CRP levels did not correlate with the elapsed
ime since the onset of symptoms or since diagnosis. In
TEPH patients, PAP was predictive for adverse outcome
hazard ratio: 1.05, 95% CI: 1.01 to 1.10, p  0.02),
hereas CRP was not.
ffect of medical treatment in PAH. A second evaluation
as performed in 24 PAH patients, mean 28 months (range
to 82 months) after start of disease-specific medication. In
3 of the 37 PAH patients who were already treated at
nclusion, the baseline evaluation was retrospectively re-
rieved from the reference center database. In the whole
roup of 57 PAH patients, an average period of 40-month
reatment (range 9 to 82 months) resulted in significant
ecreases in PVR (134 397 dyn·s·cm5, p 0.003) and
YHA functional class (0.3 0.8, p 0.01) and increase
nivariate and Multivariate Analysis Relating Survival to Selected
Table 2 Univariate and Multivariate Analysis Relating Survival
Univariate Analysis
Variables Hazard Ratio 95% Confidence Interval
PAH
Age 1.062 1.024–1.100
Etiology 1.293 1.054–1.587
NYHA functional class
II vs. I 0.575 0.252–1.313
III vs. I 2.203 1.102–4.402
IV vs. I 2.035 0.813–5.096
6MWD 0.995 0.992–0.997
RAP 1.128 1.062–1.198
LogCRP 3.857 1.793–8.298
IPAH
6MWD 0.995 0.991–0.999
LogCRP 6.374 1.616–25.150
PAH treatment naive
Age 1.048 1.002–1.096
Etiology 1.178 0.886–1.568
6MWD 0.994 0.991–0.998
RAP 1.158 1.074–1.248
LogCRP 3.336 1.387–8.235
tiology included IPAH, PAH associated to connective tissue disease, congenital heart disease, p
nalysis, variables were selected by stepwise selection and reported if the value of p  0.10. NYH
CRP  C-reactive protein; IPAH  idiopathic pulmonary arterial hypertension; other abbreviation cardiac index (0.38  0.97 l·min1·m2, p  0.0001), 0ithout any significant change in RAP, PAP, 6MWD, and
RP levels. However, when patients were stratified accord-
ng to treatment effect on CRP levels, patients normalizing
RP levels under ULN (responders, n  29, 3.7  6.8,
 0.0001) displayed a concomitant decrease in NYHA
unctional class (0.3  0.8, p  0.05) and increase in
ardiac index (0.29 0.78 l·min1·m2, p 0.002). Survival
aplan-Meier analysis showed that responders had a higher
urvival rate (84% vs. 61% at 3 years, p  0.05) (Fig. 3).
Twenty-nine PAH patients were treated with endothelin
eceptor antagonists, 17 with prostacyclin analogues, 5 with
hosphodiesterase-5 inhibitors, 5 with a combination of 2
f them, and 1 with calcium-channel blockers. The propor-
ion of patients receiving prostacyclin analogues was signif-
cantly higher among the responders compared with the
onresponders (55% vs. 17%, p  0.002). Patients receiving
rostacyclin analogues displayed significantly lower CRP
evels (2.7 mg·l1, 95% CI: 1.8 to 3.9 mg·l1 vs. 5.1 mg·l1,
5% CI: 3.5 to 7.4 mg·l1; p  0.01).
ffect of surgical treatment in CTEPH. A second eval-
ation was performed in 23 CTEPH patients, mean 12
onths (range 2 to 22 months) after PEA. Circulating CRP
evels were significantly decreased (4.0 mg·l1, 95% CI: 2.8
o 5.8 mg·l1 vs. 5.1 mg·l1, 95% CI: 3.5 to 7.4 mg·l1;
 0.004) (Fig. 4), with concomitant decreases in RAP
3.1  5.4 mm Hg, p  0.01), PAP (15  12 mm Hg,
 0.0001), PVR (522  433 dyn·s·cm5, p  0.0001),
nd NYHA functional class (0.9  1.0, p  0.0002) and
ncrease in cardiac index (0.59  0.55 min1·m2, p 
ine Variables
lected Baseline Variables
Multivariate Analysis
p Value Hazard Ratio 95% Confidence Interval p Value
0.0010 — — —
0.0138 1.354 1.085–1.691 0.007
0.0202 — — —
0.19 — — —
0.0254 — — —
0.13 — — —
0.0001 0.996 0.993–0.999 0.005
0.0001 1.068 1.000–1.141 0.049
0.0006 3.115 1.353–7.172 0.008
0.021 0.995 0.990–0.999 0.026
0.0082 10.666 1.213–93.747 0.033
0.04 — — —
0.26 1.449 1.050–1.999 0.024
0.0017 0.993 0.989–0.998 0.004
0.0001 1.111 1.027–1.201 0.008
0.010 3.716 1.386–9.965 0.009
pertension, myeloproliferative disorders, and pulmonary veno-occlusive disease. In multivariate
tional class was coded as dummy variables in which class I was set as reference.
Table 1.Basel
to Se
ortal hy
A func
ns as in.0002) and 6MWD (95  99 m, p  0.0003).
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he aim of the present study was to investigate a potential
ole of CRP in predicting the outcome in patients with
AH and CTEPH. The results revealed that CRP levels
ere higher in patients with pulmonary hypertension com-
ared with those in control subjects. Severe pulmonary
ypertension was associated with increased circulating CRP
evels in PAH. CRP predicted mortality and clinical wors-
ning of PAH patients. An increase in CRP levels under
isease-specific medication also predicted mortality of PAH
atients. The novelty of the present study is a potential role
f CRP as a predictor of adverse outcome and response to
herapy in PAH.
nflammation in PAH: circulating CRP as the main
ndicator. Several studies have already argued for a role of
oth systemic and local inflammation in PAH (3–6). This
ts with our findings demonstrating an increase in circulat-
ng CRP levels in PAH patients compared with those in
ontrol subjects. Elevated levels of CRP predict the risk of
ecurrent ischemia and death among patients with known
therosclerotic disease. Elevated CRP has been recently
roposed as a predictor of pulmonary hypertension in
aucher disease (12). In chronic obstructive pulmonary
isease, also associated with systemic inflammation, CRP
as been identified as a marker of prognosis (13). Chronic
bstructive pulmonary disease patients with pulmonary
ypertension display higher plasma levels of CRP (14). The
resent study is the first that evidenced circulating CRP as
n independent predictor of mortality and prognosis in
atients with PAH. In accordance, besides supranormal
RP, poor survival was also associated with higher RAP
nd NYHA functional class and lower 6MWD, known as
urrogate markers of survival in PAH (15,16). Nowadays,
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Figure 3 Survival of Treated PAH Patients
According to the Change in CRP Levels
Kaplan-Meier curve comparing the survival rate of treated PAH patients (n 
57) according to the change in CRP levels under therapy. Responders are
defined as patients normalizing their CRP values under the upper limits of nor-
mal. Abbreviations as in Figure 1.YHA functional class and 6MWD are widely recognizeds important and useful primary end points for clinical trials
17,18). Our findings are even strengthened by the remain-
ng role of CRP as an independent risk factor in predicting
dverse outcome in more homogeneous groups of patients
ike IPAH or PAH patients without any disease-specific
reatment.
The N-terminal fragment of brain natriuretic peptide
NT-proBNP) is commonly used as a marker for diagnosis,
everity, and prognosis of patients with congestive heart
ailure (19). NT-proBNP is so far the only biomarker
urrently used in the practice as a prognostic parameter (20)
nd to stratify disease severity (21) in patients with pulmo-
ary hypertension. According to our present findings, we
ay consider including CRP as an additional biomarker in
he evaluation of PAH.
RP and medical treatment in PAH. In accordance with
revious reports highlighting the importance of improve-
ent in exercise capacity, NYHA functional class, and
ardiac index in evaluating effects of treatment in PAH
22,23), we have observed that a 40-month period of
pecific disease treatment resulted in a decrease in PVR and
YHA functional class and an increase in cardiac index.
ny association between the inflammation status of PAH
atients and treatment effect has been established so far.
ur present findings concerning 57 PAH-treated patients
ighlight a potential role of CRP in predicting response to
herapy. In addition, the treated patients normalizing CRP
nder ULN (5 mg·l1) had a significantly better survival
ccompanied by a decrease in NYHA functional class and
n increase in cardiac index. The better survival observed in
reated patients normalizing CRP under ULN was also
ssociated with a higher proportion under prostacyclin
nalogues, in agreement with previous observations report-
ng an enhanced survival in patients under long-term
ntravenous epoprostenol infusion (23,24).
NT-proBNP decreases together with an improvement in
emodynamics in treated PAH patients (25). Consequently,
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1
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)
Figure 4 Effect of Surgical Treatment
on CRP Levels in CTEPH Patients
CRP levels were measured in the plasma of CTEPH patients (n  23) before
and after pulmonary endarterectomy (PEA). Black lines represent geometric
mean. Abbreviations as in Figure 1.
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April 7, 2009:1211–8 CRP and Pulmonary Arterial Hypertensionosing NT-proBNP and CRP may help to orientate ther-
peutic options.
RP and surgical treatment in CTEPH. In our popula-
ion of CTEPH patients who underwent a PEA, a signif-
cantly decrease in circulating CRP levels has been observed
2 months after surgery, suggesting an improvement in
heir inflammatory status. Similarly, Langer et al. (26) have
ound elevated tumor necrosis factor-alpha levels in
TEPH patients before PEA, which dropped after the
urgery. Besides the decrease in tumor necrosis factor-alpha
nd CRP after surgical treatment in CTEPH, NT-
roBNP, also used as a noninvasive marker of the severity of
ight ventricular dysfunction in CTEPH (27), is decreasing
nder oral endothelin receptor antagonist (28) or subcuta-
eous prostacyclin analog therapy (29) in inoperable
TEPH patients. Although CRP could not be identified as
prognostic factor to predict adverse outcome of PEA in
ur population of operated CTEPH patients, CRP may be
seful to evaluate both medical and surgical treatment
fficacy in CTEPH.
elevance of the study. An interesting finding and unex-
lored aspect of the study is the predictive value of CRP for
he outcome of PAH patients and its sensitivity to disease-
pecific medication. The noninvasive feature associated with
he low cost of the measurement of CRP minimizes risks for
he patients and deserves consideration to include it in the
valuation of patients with pulmonary hypertension and to
rientate the therapeutic options.
tudy limitations. The present study was exploratory and
erformed on consecutive patients coming to the reference
enter for right heart catheterization. At first line, our
rospective study only included 24 PAH patients who had
second evaluation after an average period of 28 months
nder disease-specific medication. In order to increase this
opulation and to strengthen our results, we have retrospec-
ively retrieved the baseline evaluation concerning 33 pa-
ients who were already treated at inclusion. To properly
valuate the effect of treatment on inflammatory markers,
e should extend these measurements to a larger number of
atients evaluated at a fixed time after starting disease-
pecific medications or PEA, although the present results
re promising.
ROC analysis indicated relatively low sensitivity and
pecificity for CRP in predicting survival, compared with
T-proBNP (20). However, we must emphasize that in
AH: 1) ROC analysis has never been performed for
nflammatory biomarkers; and 2) we do not expect CRP to
e the unique predictor of death.
In the present study, CRP did not correlate strongly with
emodynamics in PAH and CTEPH patients. Circulating
onocyte chemoattractant protein-1 has been found to
orrelate with PVR in CTEPH patients (8), which we did
ot confirm in our CTEPH population. A plausible expla-
ation could be that inflammation is not a linear evolving
rocess in the course of the disease (i.e., early peaks of
nflammation may occur without direct consequences on theemodynamics). However, we were not able to demonstrate
ny relationship between the length of the disease and CRP.
onclusions
he present study clearly shows that circulating CRP may
redict the severity and the outcome in PAH and that its
ensitivity to disease-specific medication may orientate thera-
eutic options.
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